Theriva Biologics, Inc. (TOVX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Theriva Biologics, Inc. on October 16, 2025, regarding a material definitive agreement entered into on the same date. The transaction closed on October 17, 2025. The Company is a Nevada corporation with principal executive offices in Rockville, Maryland, and its common stock trades on the NYSE American under the symbol "TOVX."
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $4.4 million received from the exercise of existing warrants.
- Existing Warrants Exercised: 8,092,280 shares (comprising 1,345,000 September 2024 warrants and 6,747,280 May 2025 warrants).
- Exercise Price: Reduced to $0.54 per share for the existing warrants.
- New Warrants Issued: 16,184,560 new warrants issued to holders (200% of the shares underlying the existing warrants).
- New Warrant Terms: Exercise price of $0.54 per share; 5-year term from the date of Stockholder Approval.
- Transaction Costs: A cash fee of 7.0% of aggregate gross proceeds was paid to Alliance Global Partners LP (AGP) as financial advisor.
- Use of Proceeds: Net proceeds are expected to be used for working capital.
Note: This filing does not provide specific data on revenue, profit, cash flow, margins, or total debt levels as it reports a specific capital transaction rather than periodic financial results.
Material Changes and Conditions
The primary material change is the capital raise via warrant exercise and the simultaneous issuance of new warrants. Key conditions include:
- Stockholder Approval: The new warrants cannot be exercised until the Company obtains stockholder approval for the full exercise and issuance of the underlying shares. The Company must call a meeting within 60 days of the closing date to seek this approval.
- Registration: The Company agreed to file a resale registration statement for the new warrant shares within 30 days and use commercially reasonable efforts to have it declared effective within 60 days.
- Lock-up Provisions: The Company agreed not to issue additional common stock or equivalents for 45 days following the closing date (with exceptions) and not to enter into Variable Rate Transactions for 90 days (ATM sales permitted after 5 days).
Outlook, Risks, and Contingencies
- Approval Risk: If stockholder approval is not obtained at the first meeting within 60 days, the Company must call meetings every 60 days thereafter until approval is obtained or the warrants are no longer outstanding.
- Ownership Limits: Holders cannot exercise new warrants if it would result in beneficial ownership exceeding 4.99% (or 9.99% upon election) of outstanding shares.
- Fundamental Transaction Rights: In the event of a Fundamental Transaction, holders have the right to require the Company to purchase unexercised warrants for cash based on the Black Scholes Value, subject to specific conditions regarding transactions not in the Company's control.
- Unregistered Securities: The new warrants were issued in a private placement under Section 4(a)(2) and Rule 506(b) exemptions and are not registered under the Securities Act of 1933.
Key Facts for Investor Verification
- Verify the status of the upcoming stockholder meeting required to approve the exercise of the 16,184,560 new warrants.
- Confirm the effective date of the resale registration statement for the new warrant shares.
- Monitor the Company's cash position to ensure the $4.4 million gross proceeds (net of fees) are sufficient for stated working capital needs.
- Review the definitive Warrant Inducement Agreement (Exhibit 10.1) for specific exceptions to the lock-up provisions.
- Check for any subsequent filings regarding the outcome of the stockholder vote on the new warrants.